PRESS RELEASE
OTR Therapeutics to Present Data from Two Oncology Programs at the 38th EORTC-NCI-AACR Symposium
November 18, 2026

November 18, 2026 — OTR Therapeutics, a clinical-stage biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, today announced that it will present two posters at the 38th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, to be held November 18-20 in Barcelona, Spain.

 

Title: A next-generation AR-BRD4 RIPTAC with enhanced potency and selectivity for AR-positive prostate cancer 

Abstract No.: PB-113

Date and Time: Nov 20, 2026, 09:00-15:00  (CET)

Session: New drugs

 

About OTR AR-BRD4 RIPTAC

RIPTAC is an induced-proximity modality that utilizes a hetero-bifunctional small molecule to recruit a tumor-specific protein into proximity with an effector protein, forming a ternary complex that selectively disrupts effector protein function in cells expressing the target protein. HLD-0915 is the first AR-BRD4 RIPTAC that entered clinical evaluation and showed promising efficacy in AR-expressing mCRPC. OTR has discovered and characterized next-generation AR-BRD4 RIPTAC molecules with greater activities in inhibiting AR-positive tumor growth but minimal effects in AR-negative settings, suggesting potential broader therapeutic windows in clinic.

 

Title: OTR-8100, a potent and selective EED inhibitor, demonstrates synergistic anti-tumor activity with targeted therapies in multiple solid tumors

Abstract No.: PB-122

Date and Time: Nov 18, 2026, 12:00-19:00  (CET)

Session: Epigenetic modulators (HDAC Bromodomain modulators, EZH2)

 

About OTR-8100

OTR-8100 is a potent, selective EED inhibitor designed to suppress PRC2-mediated oncogenic transcriptional programs. In a first-in-human Phase 1 study in patients with hematologic malignancies and other advanced tumors, it has demonstrated preliminary efficacy with favorable safety and pharmacokinetic/pharmacodynamic (PK/PD) profiles, supporting further development in other indications as a monotherapy or in combination. To expand its therapeutic potential into solid tumors, we conducted a series of preclinical translational studies evaluating OTR-8100 both as a single agent and in combination with other targeted therapies. Based on these data, OTR-8100 is currently being evaluated in a Phase 1 clinical study in patients with prostate cancer. Together, these preclinical and early clinical data support further development of OTR-8100 as a promising epigenetic-targeting therapy with broad potential for combination treatment in multiple solid tumors.

 

About the 38th EORTC-NCI-AACR Symposium

Organized by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI), and the American Association for Cancer Research (AACR), the 2026 Symposium gathers leading academics, scientists, and pharmaceutical industry experts from around the world. This event serves as a platform to explore groundbreaking advancements in drug development, refine target selection strategies, and assess the influence of new molecular biology discoveries. More information visit www.eortc.org/ena

 

About OTR Therapeutics

OTR Therapeutics is a clinical-stage biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies for critical diseases with high unmet medical needs. With a strategic focus on oncology, immunology and inflammation, and cardiometabolic diseases, we discover and acquire distinctive assets in preclinical and early clinical stages, and accelerate their development into differentiated, clinically impactful treatments through our R&D hub built for speed, quality and efficiency. By combining scientific rigor with agile partnerships, we deliver exceptional value to our partners and patients worldwide. From our advanced R&D center in Shanghai’s Zhangjiang Hi-Tech Park, we actively collaborate with a global network of partners across the US, Europe, and Asia. www.otr-tx.com


Back

Copyright © 2025 OTR Therapeutics. All rights reserved.

Terms and Conditions |Privacy Policy